Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.56 |
| ▸ | KCNJ1 | P48048 | 7/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.52 |
| ▸ | HTR2A | P28223 | 2/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 2/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2295138 | 1.00 | SIGMAR1 (0.56) | SIGMAR1KCNJ1KCNH2HTR2AHRH3 | |
| SCHEMBL9663530 | 0.94 | KCNJ1 (0.59) | SIGMAR1KCNJ1KCNH2HRH3MAOA | |
| SCHEMBL2293884 | 0.88 | CNR2 (0.58) | KCNJ1CNR2 | |
| SCHEMBL16796559 | 0.88 | CNR2 (0.58) | KCNJ1CNR2 | |
| SCHEMBL2295758 | 0.88 | CNR2 (0.58) | KCNJ1CNR2 | |
| Hydrochloric Acid SCHEMBL16796550 | 0.87 | CNR2 (0.57) | KCNJ1CNR2 | |
| Hydrochloric Acid SCHEMBL16796548 | 0.87 | CNR2 (0.57) | KCNJ1CNR2 | |
| SCHEMBL9523708 | 0.85 | CNR2 (0.58) | SIGMAR1CNR2 | |
| SCHEMBL2290559 | 0.82 | MEN1 (0.58) | SIGMAR1CNR2 | |
| SCHEMBL2294726 | 0.82 | CNR2 (0.49) | CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156804-A1 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-06-18 | — | — | US | claimed |
| EP-1910320-A2 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-04-16 | — | — | EP | claimed |
| WO-2007011065-A2 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-01-25 | — | — | WO | claimed |
| US-20110257392-A1 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | SANOFI-AVENTIS (FR) | 2011-10-20 | — | — | US | disclosed |
| US-20110251385-A1 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | SANOFI-AVENTIS (FR) | 2011-10-13 | — | — | US | disclosed |
| US-7994315-B2 | Intermediate compound for synthesizing pharmaceutical agent and production method thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-08-09 | — | — | US | disclosed |
| EP-2221305-A1 | Method for synthesizing intermediate compound for synthesizing a pharmaceutical agent | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-08-25 | — | — | EP | disclosed |
| EP-2221304-A1 | Method for synthesizing intermediate compound for synthesizing a pharmaceutical agent | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-08-25 | — | — | EP | disclosed |
| US-20090156804-A1 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-06-18 | — | — | US | disclosed |
| EP-1910320-A2 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007011065-A2 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257392-A1 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | MAPT, PSEN1, PSEN2 | SIGMAR1 3382/4885KCNJ1 2690/4885KCNH2 3795/4885 |
| US-20110251385-A1 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | MAPT, PSEN1, PSEN2 | SIGMAR1 3382/4885KCNJ1 2690/4885KCNH2 3795/4885 |
| US-20090156804-A1 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | MAPT, PSEN1, PSEN2 | SIGMAR1 3382/4885KCNJ1 2690/4885KCNH2 3795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.